Company performance
Add to research
Current Price
as of Mar 14, 2025$19.73
P/E Ratio
N/A
Market Cap
$1.75B
- DHCA
Description
Add to research
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Metrics
Add to research
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerTVTX
- Price$19.73+3.14%
Trading Information
- Market cap$1.75B
- Float98.50%
- Average Daily Volume (1m)1,695,218
- Average Daily Volume (3m)1,593,157
- EPS-$4.08
Company
- Revenue$233.17M
- Rev growth (1yr)60.55%
- Net income-$320.63M
- Gross margin78.00%
- EBITDA margin-91.19%
- EBITDA-$212.63M
- EV$1.41B
- EV/Revenue6.03
- P/EN/A
- P/S6.68
- P/B29.21
- Debt/Equity679.76
Documents
Add to research
SEC Filings
Earnings Calls
Factset Street Account